PT-141 Protocol

The Desire

A melanocortin-based peptide studied for its potential role in sexual health and wellness. Acts via central nervous system pathways rather than the vascular system. Suitability is assessed by your prescribing physician.

PT-141 has been studied in relation to sexual health and wellness in both men and women. Research has explored its central pathway mechanism. Suitability and expected outcomes are assessed by your prescribing physician.

What is PT-141?

PT-141 (Bremelanotide) is a melanocortin-based peptide studied for its potential effects on sexual health and wellness in both men and women. Unlike medications that work primarily through the vascular system, PT-141 is understood to act through the central nervous system, binding to melanocortin receptors in the brain to influence arousal pathways. A pharmaceutical version received FDA approval for hypoactive sexual desire disorder in premenopausal women in 2019, providing a regulated clinical foundation for this class of peptide.

PT-141 in the UAE

PT-141 is available as a physician-supervised prescription protocol through UAE Peptide Clinic. A clinical consultation with a DHA-registered physician is required to assess suitability, review health history, and rule out contraindications. The peptide is typically administered as a subcutaneous injection 2 to 4 hours before activity, at doses of 1 to 2mg as directed by your physician. It is supplied in pharmaceutical-grade vials, cold-chain delivered across Dubai and all UAE emirates in discreet packaging.

Who uses PT-141?

PT-141 is explored by both men and women seeking physician-supervised support for sexual health and wellness. Its central nervous system mechanism makes it distinct from other approaches and of potential interest to patients for whom vascular-mechanism options are less suitable. All cases are assessed individually, and the protocol is prescribed only where the physician determines it clinically appropriate.